Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2002 · The Lancet · 4,137 citations
https://doi.org/10.1016/s0140-6736(02)08512-4
J
Jean‐Frédéric Colombel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.3K
Papers
94.9K
Citations
139
h-index
549
i10-index
Jean‐Frédéric Colombel is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 139, co-authored 1147 publications.
ORCID: 0000-0001-6472-249XPapers by this author
worksInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 · New England Journal of Medicine · 3,852 citations
https://doi.org/10.1056/nejmoa050516
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 · New England Journal of Medicine · 2,779 citations
https://doi.org/10.1056/nejmoa1215734
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 · New England Journal of Medicine · 2,658 citations
https://doi.org/10.1056/nejmoa1215739
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 · Gastroenterology · 2,504 citations
https://doi.org/10.1053/j.gastro.2020.12.031
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
2015 · The American Journal of Gastroenterology · 1,784 citations
https://doi.org/10.1038/ajg.2015.233
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat